{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T07:32:31Z","timestamp":1793431951726,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T00:00:00Z","timestamp":1578528000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T00:00:00Z","timestamp":1578528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Health & Welfare, Republic of Korea","award":["HI19C0577"],"award-info":[{"award-number":["HI19C0577"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We sought to describe corneal epithelial changes after using epidermal (EGFR) or fibroblast growth factor receptor (FGFR) inhibitors as chemotherapy and to clarify incidence and prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials<\/jats:title>\n                    <jats:p>Retrospective chart review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 6871 patients and 17 EGFR or FGFR inhibitors, 1161 patients (16.9%) referred for ophthalmologic examination. In total, 1145 patients had disease-related or unrelated ocular complications. Among 16 patients with treatment-related ocular complications, three patients had treatment-related radiation retinopathy and one patient showed treatment-related corneal ulcer. Finally the authors identified that, in 12 patients, three EGFR inhibitors and two FGFR inhibitors caused corneal epithelial lesions. Vandetanib, Osimertinib, and ABT-414 caused vortex keratopathy in nine patients, while ASP-5878 and FPA-144 caused epithelial changes resembling corneal dysmaturation in three patients. The mean interval until symptoms appeared was 246\u2009days with vandetanib, 196\u2009days with osimertinib, 30\u2009days with ABT-414, 55\u2009days with ASP-5878, and 70\u2009days with FPA-144. The mean of the lowest logarithm of minimal angle of resolution visual acuity results of the right and left eyes after chemotherapy were 0.338 and 0.413. The incidence rates of epithelial changes were 15.79% with vandetanib, 0.5% with osimertinib, 100% with ABT-414, 50.0% with ASP-5878, and 18.2% with FPA-144. After excluding deceased patients and those who were lost to follow-up or still undergoing treatment, we confirmed the reversibility of corneal lesions after the discontinuation of each agent. Seven patients showed full recovery of their vision and corneal epithelium, while three achieved a partial level of recovery. Although patients diagnosed with glioblastoma used prophylactic topical steroids before and during ABT-414 therapy, all developed vortex keratopathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>EGFR and FGFR inhibitors are chemotherapy agents that could make corneal epithelial changes. Contrary to the low probability of ocular complication with old EGFR drugs, recently introduced EGFR and FGFR agents showed a high incidence of ocular complication with severe vision distortion. Doctors should forewarn patients planning chemotherapy with these agents that decreased visual acuity could develop due to corneal epithelial changes and also reassure them that the condition could be improved after the end of treatment without the use of steroid eye drops.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>This study was approved by the institutional review board (IRB) of Samsung Medical Center (IRB no. 2019\u201304-027) and was conducted according to the principles expressed in the Declaration of Helsinki.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12886-019-1285-9","type":"journal-article","created":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T11:02:27Z","timestamp":1578567747000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors"],"prefix":"10.1186","volume":"20","author":[{"given":"Eunhae","family":"Shin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Hui","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jisang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do-Hyun","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keunchil","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung-Ju","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Ki","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeeyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Seok","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Mu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Ae","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Young","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,9]]},"reference":[{"key":"1285_CR1","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/j.ophtha.2012.03.002","volume":"119","author":"A Saint-Jean","year":"2012","unstructured":"Saint-Jean A, Sainz de la Maza M, Morral M, Torras J, Quintana R, Molina JJ, et al. Ocular adverse events of systemic inhibitors of the epidermal growth factor receptor: report of 5 cases. Ophthalmology. 2012;119:1798\u2013802.","journal-title":"Ophthalmology"},{"key":"1285_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3109\/15569527.2010.498398","volume":"30","author":"EB Marquez","year":"2011","unstructured":"Marquez EB, De Ortueta D, Royo SB, Martinez-Carpio PA. Epidermal growth factor receptor in corneal damage: update and new insights from recent reports. Cutan Ocul Toxicol. 2011;30:7\u201314.","journal-title":"Cutan Ocul Toxicol"},{"key":"1285_CR3","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/nrc.2017.8","volume":"17","author":"IS Babina","year":"2017","unstructured":"Babina IS, Turner NC. Advances and challenges in targeting FGFR signalling in cancer. Nat Rev Cancer. 2017;17:318\u201332.","journal-title":"Nat Rev Cancer"},{"key":"1285_CR4","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s00520-012-1645-y","volume":"21","author":"DS Borkar","year":"2013","unstructured":"Borkar DS, Lacouture ME, Basti S. Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review. Support Care Cancer. 2013;21:1167\u201374.","journal-title":"Support Care Cancer"},{"key":"1285_CR5","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.survophthal.2016.11.008","volume":"62","author":"MB Raizman","year":"2017","unstructured":"Raizman MB, Hamrah P, Holland EJ, Kim T, Mah FS, Rapuano CJ, et al. Drug-induced corneal epithelial changes. Surv Ophthalmol. 2017;62:286\u2013301.","journal-title":"Surv Ophthalmol"},{"key":"1285_CR6","first-page":"965","volume":"19","author":"DA Reardon","year":"2017","unstructured":"Reardon DA, Lassman AB, van den Bent M, Kumthekar P, Merrell R, Scott AM, et al. Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma. Neuro-Oncology. 2017;19:965\u201375.","journal-title":"Neuro-Oncology"},{"key":"1285_CR7","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1158\/1535-7163.MCT-15-0901","volume":"15","author":"AC Phillips","year":"2016","unstructured":"Phillips AC, Boghaert ER, Vaidya KS, Mitten MJ, Norvell S, Falls HD, et al. ABT-414, an antibody-drug conjugate targeting a tumor-selective EGFR epitope. Mol Cancer Ther. 2016;15:661\u20139.","journal-title":"Mol Cancer Ther"},{"key":"1285_CR8","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/1535-7163.MCT-16-0188","volume":"16","author":"T Futami","year":"2017","unstructured":"Futami T, Okada H, Kihara R, Kawase T, Nakayama A, Suzuki T, et al. ASP5878, a novel inhibitor of FGFR1, 2, 3, and 4, inhibits the growth of FGF19-expressing hepatocellular carcinoma. Mol Cancer Ther. 2017;16:68\u201375.","journal-title":"Mol Cancer Ther"},{"issue":"4_suppl","key":"1285_CR9","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1200\/jco.2016.34.4_suppl.140","volume":"34","author":"Johanna C. Bendell","year":"2016","unstructured":"Bendell JC, Rogers S, Xiang H, Pierce KL, Krishnan K, Sikorski RS, Hambleton J, Rasco DW. FPA144-001: A first in human study of FPA 144, an ADCC-enhanced, FGFR2b isoform-selective monoclonal antibody in patients with advanced solid tumors. 2016;34(4_suppl):140. https:\/\/doi.org\/10.1200\/jco.2016.34.4_suppl.140.","journal-title":"Journal of Clinical Oncology"},{"key":"1285_CR10","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3341\/kjo.2011.25.5.355","volume":"25","author":"J Ahn","year":"2011","unstructured":"Ahn J, Wee WR, Lee JH, Hyon JY. Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer. Korean J Ophthalmol. 2011;25:355\u20137.","journal-title":"Korean J Ophthalmol"},{"key":"1285_CR11","doi-asserted-by":"publisher","first-page":"5489","DOI":"10.2147\/OTT.S114722","volume":"9","author":"H Zhang","year":"2016","unstructured":"Zhang H. Osimertinib making a breakthrough in lung cancer targeted therapy. Onco Targets Ther. 2016;9:5489\u201393.","journal-title":"Onco Targets Ther"},{"key":"1285_CR12","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1097\/JTO.0000000000000634","volume":"10","author":"PL Chia","year":"2015","unstructured":"Chia PL, John T. Vortex Keratopathy presumed secondary to AZD9291. J Thorac Oncol. 2015;10:1807\u20138.","journal-title":"J Thorac Oncol"},{"key":"1285_CR13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/BF00139581","volume":"4","author":"DJ D'Amico","year":"1981","unstructured":"D'Amico DJ, Kenyon KR. Drug-induced lipidoses of the cornea and conjunctiva. Int Ophthalmol. 1981;4:67\u201376.","journal-title":"Int Ophthalmol"},{"key":"1285_CR14","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.saa.2017.08.051","volume":"189","author":"MZ Kabir","year":"2018","unstructured":"Kabir MZ, Hamzah NAB, Ghani H, Mohamad SB, Alias Z, Tayyab S. Biophysical and computational characterization of vandetanib-lysozyme interaction. Spectrochim Acta A Mol Biomol Spectrosc. 2018;189:485\u201394.","journal-title":"Spectrochim Acta A Mol Biomol Spectrosc"},{"key":"1285_CR15","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","volume":"8","author":"H Donaghy","year":"2016","unstructured":"Donaghy H. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs. 2016;8:659\u201371.","journal-title":"MAbs"},{"key":"1285_CR16","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1016\/j.bmcl.2014.10.021","volume":"24","author":"H Bouchard","year":"2014","unstructured":"Bouchard H, Viskov C, Garcia-Echeverria C. Antibody-drug conjugates-a new wave of cancer drugs. Bioorg Med Chem Lett. 2014;24:5357\u201363.","journal-title":"Bioorg Med Chem Lett"},{"key":"1285_CR17","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1089\/jop.2015.0064","volume":"31","author":"JS Eaton","year":"2015","unstructured":"Eaton JS, Miller PE, Mannis MJ, Murphy CJ. Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J Ocul Pharmacol Ther. 2015;31:589\u2013604.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1285_CR18","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/ardp.201600063","volume":"349","author":"M Hossam","year":"2016","unstructured":"Hossam M, Lasheen DS, Abouzid KA. Covalent EGFR inhibitors: binding mechanisms, synthetic approaches, and clinical profiles. Arch Pharm (Weinheim). 2016;349:573\u201393.","journal-title":"Arch Pharm (Weinheim)"},{"key":"1285_CR19","doi-asserted-by":"publisher","first-page":"xv","DOI":"10.1016\/B978-0-323-06387-6.00006-4","volume-title":"Cornea","author":"Jay H Krachmer","year":"2011","unstructured":"Krachmer JH. Mannis MJ, Holland EJ. Cornea: Fundamentals, Diagnosis and Management. vol. one, 3rd edn. New York: Mosby Elsevier; 2011."},{"key":"1285_CR20","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00280-017-3451-1","volume":"80","author":"M van den Bent","year":"2017","unstructured":"van den Bent M, Gan HK, Lassman AB, Kumthekar P, Merrell R, Butowski N, et al. Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study. Cancer Chemother Pharmacol. 2017;80:1209\u201317.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1285_CR21","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/annonc\/mdw559","volume":"28","author":"SH Lee","year":"2017","unstructured":"Lee SH, Lee JK, Ahn MJ, Kim DW, Sun JM, Keam B, et al. Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial. Ann Oncol. 2017;28:292\u20137.","journal-title":"Ann Oncol"},{"key":"1285_CR22","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1200\/JCO.2010.28.5981","volume":"29","author":"RB Natale","year":"2011","unstructured":"Natale RB, Thongprasert S, Greco FA, Thomas M, Tsai CM, Sunpaweravong P, et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2011;29:1059\u201366.","journal-title":"J Clin Oncol"},{"key":"1285_CR23","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1200\/JCO.2017.35.15_suppl.4067","volume":"35","author":"DVT Catenacci","year":"2017","unstructured":"Catenacci DVT, Rha SY, Bang Y-J, Wainberg ZA, Chao J, Lee KW, et al. Updated antitumor activity and safety of FPA144, an ADCC-enhanced, FGFR2b isoform-specific monoclonal antibody, in patients with FGFR2b+ gastric cancer. J Clin Oncol. 2017;35:4067.","journal-title":"J Clin Oncol"},{"key":"1285_CR24","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1007\/s00417-019-04337-8","volume":"257","author":"AL Kunkler","year":"2019","unstructured":"Kunkler AL, Binkley EM, Mantopoulos D, Hendershot AJ, Ohr MP, Kendra KL, et al. Known and novel ocular toxicities of biologics, targeted agents, and traditional chemotherapeutics. Graefes Arch Clin Exp Ophthalmol. 2019;257:1771\u201381.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1285_CR25","doi-asserted-by":"publisher","first-page":"e110","DOI":"10.1097\/OPX.0000000000000571","volume":"92","author":"A Kord Valeshabad","year":"2015","unstructured":"Kord Valeshabad A, Mieler WF, Setlur V, Thomas M, Shahidi M. Posterior segment toxicity after gemcitabine and docetaxel chemotherapy. Optom Vis Sci. 2015;92:e110\u20133.","journal-title":"Optom Vis Sci"},{"key":"1285_CR26","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","volume":"21","author":"CF Thorn","year":"2011","unstructured":"Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics. 2011;21:440\u20136.","journal-title":"Pharmacogenet Genomics"},{"key":"1285_CR27","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1089\/jop.2018.0019","volume":"34","author":"FT Fraunfelder","year":"2018","unstructured":"Fraunfelder FT, Fraunfelder FW. Oral anti-vascular endothelial growth factor drugs and ocular adverse events. J Ocul Pharmacol Ther. 2018;34:432\u20135.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1285_CR28","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1158\/1078-0432.CCR-15-0600","volume":"21","author":"SJ Casak","year":"2015","unstructured":"Casak SJ, Fashoyin-Aje I, Lemery SJ, Zhang L, Jin R, Li H, et al. FDA approval summary: Ramucirumab for gastric cancer. Clin Cancer Res. 2015;21:3372\u20136.","journal-title":"Clin Cancer Res"},{"key":"1285_CR29","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s10549-013-2630-y","volume":"140","author":"E Paplomata","year":"2013","unstructured":"Paplomata E, Zelnak A, O'Regan R. Everolimus: side effect profile and management of toxicities in breast cancer. Breast Cancer Res Treat. 2013;140:453\u201362.","journal-title":"Breast Cancer Res Treat"},{"key":"1285_CR30","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1159\/000322675","volume":"3","author":"M Mesquida","year":"2010","unstructured":"Mesquida M, Sanchez-Dalmau B, Ortiz-Perez S, Pelegrin L, Molina-Fernandez JJ, Figueras-Roca M, et al. Oxaliplatin-related ocular toxicity. Case Rep Oncol. 2010;3:423\u20137.","journal-title":"Case Rep Oncol"},{"key":"1285_CR31","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00002018-200124050-00002","volume":"24","author":"FG Jansman","year":"2001","unstructured":"Jansman FG, Sleijfer DT, de Graaf JC, Coenen JL, Brouwers JR. Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer. Drug Saf. 2001;24:353\u201367.","journal-title":"Drug Saf"},{"key":"1285_CR32","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1159\/000444047","volume":"7","author":"D Todokoro","year":"2016","unstructured":"Todokoro D, Itakura H, Ibe T, Kishi S. Anterior uveitis caused by ocular side effects of Afatinib: a case report. Case Rep Ophthalmol. 2016;7:74\u20138.","journal-title":"Case Rep Ophthalmol"},{"key":"1285_CR33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4321\/S1885-642X2006000200001","volume":"4","author":"AE Omoti","year":"2006","unstructured":"Omoti AE, Omoti CE. Ocular toxicity of systemic anticancer chemotherapy. Pharm Pract (Granada). 2006;4:55\u20139.","journal-title":"Pharm Pract (Granada)"},{"key":"1285_CR34","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/0002-9394(89)90866-0","volume":"108","author":"CF Curran","year":"1989","unstructured":"Curran CF, Luce JK. Ocular adverse reactions associated with adriamycin (doxorubicin). Am J Ophthalmol. 1989;108:709\u201311.","journal-title":"Am J Ophthalmol"},{"key":"1285_CR35","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1097\/TP.0000000000000551","volume":"98","author":"S Touhami","year":"2014","unstructured":"Touhami S, Arzouk N, Darugar A, Heron E, Clarencon F, Bodaghi B, et al. Everolimus-induced posterior reversible encephalopathy syndrome and bilateral optic neuropathy after kidney transplantation. Transplantation. 2014;98:e102\u20134.","journal-title":"Transplantation"},{"key":"1285_CR36","first-page":"379132","volume":"2012","author":"E Ibrahim","year":"2012","unstructured":"Ibrahim E, Dean WH, Price N, Gomaa A, Ayre G, Guglani S, et al. Perforating corneal ulceration in a patient with lung metastatic adenocarcinoma treated with gefitinib: a case report. Case Rep Ophthalmol Med. 2012;2012:379132.","journal-title":"Case Rep Ophthalmol Med"},{"key":"1285_CR37","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/sj.eye.6701630","volume":"19","author":"AB Tullo","year":"2005","unstructured":"Tullo AB, Esmaeli B, Murray PI, Bristow E, Forsythe BJ, Faulkner K. Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (\u2018Iressa\u2019, ZD1839) in Phase I and II clinical trials. Eye (Lond). 2005;19:729\u201338.","journal-title":"Eye (Lond)"},{"key":"1285_CR38","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/ICB.0000000000000471","volume":"12","author":"JL Kovach","year":"2018","unstructured":"Kovach JL. Gemcitabine-induced retinopathy. Retin Cases Brief Rep. 2018;12:240\u20131.","journal-title":"Retin Cases Brief Rep"},{"key":"1285_CR39","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00280-016-3138-z","volume":"78","author":"T Kawakami","year":"2016","unstructured":"Kawakami T, Machida N, Yasui H, Kawahira M, Kawai S, Kito Y, et al. Efficacy and safety of irinotecan monotherapy as third-line treatment for advanced gastric cancer. Cancer Chemother Pharmacol. 2016;78:809\u201314.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1285_CR40","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/OPX.0000000000000430","volume":"92","author":"BK Yildiz","year":"2015","unstructured":"Yildiz BK, Ozdek S, Demirci U, Ceylanoglu KS, Ozmen MC, Baykara M, et al. Functional and morphological effects of systemic bevacizumab on cancer patients\u2019 eyes. Optom Vis Sci. 2015;92:102\u20136.","journal-title":"Optom Vis Sci"},{"key":"1285_CR41","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1188\/06.CJON.227-229","volume":"10","author":"D O'Dea","year":"2006","unstructured":"O'Dea D, Handy CM, Wexler A. Ocular changes with oxaliplatin. Clin J Oncol Nurs. 2006;10:227\u20139.","journal-title":"Clin J Oncol Nurs"},{"key":"1285_CR42","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1248\/bpb.b18-00444","volume":"41","author":"Y Noguchi","year":"2018","unstructured":"Noguchi Y, Kawashima Y, Maruyama M, Kawara H, Tokuyama Y, Uchiyama K, et al. Risk factors for eye disorders caused by paclitaxel: a retrospective study. Biol Pharm Bull. 2018;41:1694\u2013700.","journal-title":"Biol Pharm Bull"},{"key":"1285_CR43","doi-asserted-by":"publisher","first-page":"741","DOI":"10.4103\/0253-7613.194862","volume":"48","author":"S Kastalli","year":"2016","unstructured":"Kastalli S, Charfi O, Sahnoun R, Lakhoua G. Eyelid and feet edema induced by pemetrexed. Indian J Pharmacol. 2016;48:741\u20132.","journal-title":"Indian J Pharmacol"},{"key":"1285_CR44","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/eye.2017.222","volume":"32","author":"MT Bhatti","year":"2018","unstructured":"Bhatti MT, Salama AKS. Neuro-ophthalmic side effects of molecularly targeted cancer drugs. Eye (Lond). 2018;32:287\u2013301.","journal-title":"Eye (Lond)"},{"key":"1285_CR45","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.ijrobp.2010.07.021","volume":"81","author":"C Chen","year":"2011","unstructured":"Chen C, Damek D, Gaspar LE, Waziri A, Lillehei K, Kleinschmidt-DeMasters BK, et al. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2011;81:1066\u201374.","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-019-1285-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12886-019-1285-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-019-1285-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T19:34:25Z","timestamp":1610048065000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-019-1285-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,9]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1285"],"URL":"https:\/\/doi.org\/10.1186\/s12886-019-1285-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.10197\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.10197\/v5","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.10197\/v4","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.10197\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.10197\/v2","asserted-by":"object"}]},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,9]]},"assertion":[{"value":"30 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the institutional review board (IRB) of Samsung Medical Center (IRB no. 2019\u201304-027) and was conducted according to the principles expressed in the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable due to the nature of this study and because images are entirely unidentifiable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}